Biomarker for sensitivity to mTOR inhibitor therapy in kidney cancer
US9261498B2 · kind B2 · utility
0Cited by
1References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 17, 2006 |
| Grant date | Feb 16, 2016 |
| Priority date | — |
| Expiry date | May 20, 2030 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/4704
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention disclosed herein provides methods for the examination and/or quantification of biochemical pathways that are disregukted in pathologies such as cancer and to reagents and kits adapted for performing such methods. For example a correlation between VHL loss and mTOR inhibitor sensitivity in human kidney cancer cells is disclosed, indicating that VHL loss confers autonomous and angiogenic competitive advantages to such cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.